Cite

    Popat, U. et al. (2018). Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet. 5 (11), pp. e532-e542. [Online].